301 related articles for article (PubMed ID: 18254018)
1. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
Cochrane Database Syst Rev; 2008 Jan; 2008(1):CD003376. PubMed ID: 18254018
[TBL] [Abstract][Full Text] [Related]
2. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells G; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
Cochrane Database Syst Rev; 2008 Jan; (1):CD004523. PubMed ID: 18254053
[TBL] [Abstract][Full Text] [Related]
3. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Hsieh SC; Peterson J; Zheng C; Kelly SE; Shea B; Tugwell P
Cochrane Database Syst Rev; 2024 Apr; 4(4):CD003376. PubMed ID: 38591743
[TBL] [Abstract][Full Text] [Related]
4. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
Cochrane Database Syst Rev; 2008 Jan; (1):CD001155. PubMed ID: 18253985
[TBL] [Abstract][Full Text] [Related]
5. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Hsieh SC; Zheng C; Peterson J; Tugwell P; Liu W
Cochrane Database Syst Rev; 2022 May; 5(5):CD004523. PubMed ID: 35502787
[TBL] [Abstract][Full Text] [Related]
6. Alendronate for fracture prevention in postmenopause.
Holder KK; Kerley SS
Am Fam Physician; 2008 Sep; 78(5):579-81. PubMed ID: 18788232
[TBL] [Abstract][Full Text] [Related]
7. WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Adachi JD; Guyatt G; Papaioannou A; Robinson VA; Shea BJ; Tugwell P; Waldegger LM; Weaver B; Wells G; Zytaruk N
Cochrane Database Syst Rev; 2007 Jul; (1):CD004523. PubMed ID: 17636764
[TBL] [Abstract][Full Text] [Related]
8. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Mhaskar R; Kumar A; Miladinovic B; Djulbegovic B
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003188. PubMed ID: 29253322
[TBL] [Abstract][Full Text] [Related]
10. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
Deardorff WJ; Cenzer I; Nguyen B; Lee SJ
JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231
[TBL] [Abstract][Full Text] [Related]
11. WITHDRAWN: Etidronate for treating and preventing postmenopausal osteoporosis.
Cranney A; Adachi JD; Griffith L; Guyatt G; Krolicki N; Robinson VA; Shea BJ; Wells G
Cochrane Database Syst Rev; 2007 Jul; (1):CD003376. PubMed ID: 17636719
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
13. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis.
Reginster J-; Bianic F; Campbell R; Martin M; Williams SA; Fitzpatrick LA
Osteoporos Int; 2019 Jul; 30(7):1465-1473. PubMed ID: 30953114
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
15. Etidronate for treating and preventing postmenopausal osteoporosis.
Cranney A; Welch V; Adachi JD; Guyatt G; Krolicki N; Griffith L; Shea B; Tugwell P; Wells G
Cochrane Database Syst Rev; 2001; (4):CD003376. PubMed ID: 11687195
[TBL] [Abstract][Full Text] [Related]
16. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men.
Avenell A; Mak JC; O'Connell D
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD000227. PubMed ID: 24729336
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Hara T; Hijikata Y; Matsubara Y; Watanabe N
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
[TBL] [Abstract][Full Text] [Related]
19. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD005326. PubMed ID: 17054253
[TBL] [Abstract][Full Text] [Related]
20. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.
Harris ST; Watts NB; Jackson RD; Genant HK; Wasnich RD; Ross P; Miller PD; Licata AA; Chesnut CH
Am J Med; 1993 Dec; 95(6):557-67. PubMed ID: 8259772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]